Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites

(OaSiS Trial)

Recruiting in Palo Alto (17 mi)

+48 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Wake Forest University Health Sciences

No Placebo Group

Approved in 6 Jurisdictions

Trial Summary

What is the purpose of this trial?

Evaluate a multi-faceted training program to improve short-term smoking cessation rates (\<14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114 enrolled smokers who present for low-dose computed tomography (LDCT) lung cancer screening in 26 community-based practices.

Eligibility Criteria

Inclusion Criteria

Agrees to have NCORP research personnel serve as the study liaison and another person to serve as the cessation program champion.

Agrees to participate in all aspects of the intervention, randomization, and evaluation.

Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team.

Treatment Details

Interventions

• Smoking Cessation (Behavioural Intervention)

Participant Groups

Group I: Intervention Experimental Treatment 1 Intervention

Training of Lung Cancer Screening Personnel on implementation of the United States Public Health Service (US PHS) Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, \<14 days, 3 months, and 6 months)

Group II: Usual Care Active Control 1 Intervention

No training or performance coaching calls on personnel, just usual clinic practice. Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, \<14 days, 3 months, and 6 months)

Smoking Cessation is already approved in United States, United States, United States, European Union, European Union, European Union for the following indications:

🇺🇸 Approved in United States as Nicotine Replacement Therapy for:

• Smoking cessation

🇺🇸 Approved in United States as Bupropion for:

• Smoking cessation

🇺🇸 Approved in United States as Varenicline for:

• Smoking cessation

🇪🇺 Approved in European Union as Nicotine Replacement Therapy for:

• Smoking cessation

🇪🇺 Approved in European Union as Bupropion for:

• Smoking cessation

🇪🇺 Approved in European Union as Varenicline for:

• Smoking cessation

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University Medical Center of Southern Nevada Las Vegas, NV

Sanford South University Medical Center Fargo, ND

Aurora Saint Luke's Medical Center Milwaukee, WI

Mercy Hospital Washington Washington, MO

More Trial Locations

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences Lead Sponsor

National Cancer Institute (NCI) Collaborator

References